For Healthcare Professionals
A collaborative channel for clinicians and researchers to work with Dezawa MuseCells® and Dezawa MuseExosomes® within Thai hospital frameworks.
Overview for Healthcare Professionals
Muse Cell Thailand operationalises the Dezawa MuseCells® and Dezawa MuseExosomes®
platform in Thailand through technology transfer to Innobelle and structured
collaborations with hospitals. The aim is to move from scattered, generic “stem cell” offers to
an origin-defined, evidence-linked regenerative platform.
platform in Thailand through technology transfer to Innobelle and structured
collaborations with hospitals. The aim is to move from scattered, generic “stem cell” offers to
an origin-defined, evidence-linked regenerative platform.
Could a Dezawa Muse Program Be Right for You?
• Origin: SSEA-3+ endogenous Muse subpopulation versus heterogeneous MSCs and reprogrammed iPS/ESCs.
• Behaviour: pluripotent-like tri-lineage differentiation plus active homing and structural integration into host tissue.
• Safety: non-tumorigenic profile in preclinical models, low telomerase activity, no teratomas versus high teratoma risk with iPS/ESC.
• Mechanism: S1P-S1PR2-mediated homing, phagocytosis-induced differentiation and strong paracrine modulation.
In short, the Dezawa Muse platform occupies a unique space: high regenerative potential with a low tumour-risk profile within current evidence.
• Behaviour: pluripotent-like tri-lineage differentiation plus active homing and structural integration into host tissue.
• Safety: non-tumorigenic profile in preclinical models, low telomerase activity, no teratomas versus high teratoma risk with iPS/ESC.
• Mechanism: S1P-S1PR2-mediated homing, phagocytosis-induced differentiation and strong paracrine modulation.
In short, the Dezawa Muse platform occupies a unique space: high regenerative potential with a low tumour-risk profile within current evidence.
Dezawa MuseCells® – Clinical Concept
Dezawa MuseCells® are positioned as an allogeneic IV product with indication-specific dosing.
Early studies have examined domains such as:
• Neurology – ischemic stroke (including randomized controlled trials), ALS, cervical SCI, neonatal HIE.
• Cardiology – acute myocardial infarction (first-in-human trial).
• Organ fibrosis – chronic liver and kidney models, including adriamycin nephropathy.
• Musculoskeletal and skin – osteochondral defect repair and rare skin disorders including DEB.
These studies focus primarily on safety and feasibility with signs of functional benefit in some indications;
larger and longer-term trials remain important.
Early studies have examined domains such as:
• Neurology – ischemic stroke (including randomized controlled trials), ALS, cervical SCI, neonatal HIE.
• Cardiology – acute myocardial infarction (first-in-human trial).
• Organ fibrosis – chronic liver and kidney models, including adriamycin nephropathy.
• Musculoskeletal and skin – osteochondral defect repair and rare skin disorders including DEB.
These studies focus primarily on safety and feasibility with signs of functional benefit in some indications;
larger and longer-term trials remain important.
Dezawa MuseExosomes® – Integration Points
Dezawa MuseExosomes® are used as a cell-free extension of the Muse platform and may be considered for:
• Maintenance phases following Dezawa MuseCells® IV programs.
• Cell-free options in longevity and metabolic clinics when cell therapy is not appropriate.
• Adjunct roles in dermato-regenerative protocols where regulations allow.
MuseExosomesR are derived from Muse cells rather than generic MSCs, maintaining alignment with origin science and platform-specific signalling.
• Maintenance phases following Dezawa MuseCells® IV programs.
• Cell-free options in longevity and metabolic clinics when cell therapy is not appropriate.
• Adjunct roles in dermato-regenerative protocols where regulations allow.
MuseExosomesR are derived from Muse cells rather than generic MSCs, maintaining alignment with origin science and platform-specific signalling.
Manufacturing & Quality in Thailand
Technology transfer from Prof. Dezawa’s team to Innobelle in Thailand enables local manufacturing of Dezawa MuseCells® and Dezawa MuseExosomes® according to originator protocols. Batch-level documentation, quality control and traceability are maintained to a standard suitable for cell-based advanced therapies. Hospitals collaborate closely with Innobelle on governance, pharmacovigilance and data capture.
Collaboration Models & Referral Pathways
• Pilot Muse programs in one or two focus indications (e.g., post-stroke, post-AMI) with strict inclusion criteria.
• Expansion to multi-domain programs (neuro, cardio, chronic kidney/liver disease, orthopaedics, longevity) as experience grows.
• Registries and observational cohorts, with potential formal clinical trials in selected centres.
• Co-branded “Dezawa Muse Regenerative & Longevity Center” concepts for high- commitment institutional partners.
• Expansion to multi-domain programs (neuro, cardio, chronic kidney/liver disease, orthopaedics, longevity) as experience grows.
• Registries and observational cohorts, with potential formal clinical trials in selected centres.
• Co-branded “Dezawa Muse Regenerative & Longevity Center” concepts for high- commitment institutional partners.